Hansoh Biomedical R&D Company
Clinical trials sponsored by Hansoh Biomedical R&D Company, explained in plain language.
Now part of
Jiangsu Hansoh Pharmaceutical Group Co., Ltd.
3692
HKEX
Research and development arm of a major Chinese pharmaceutical company.
Not investment advice. Company information is shown for context only. Clinical trials frequently fail.
Advertising disclosure. Links marked "(ad)" go to partners we have a commercial relationship with, either a broker where you can trade or a stock-research service, and we may earn a commission if you open an account or subscribe. This never affects what is shown here.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- New hope for stomach cancer: targeted drug HS-20093 enters human trials Results expected Dec 2026 (estimated)
- New drug HS-20110 enters human testing for Hard-to-Treat cancers Results expected Dec 2026 (estimated)
- New hope for tough ovarian cancer: HS-20089 takes on chemo in major trial Results expected Mar 2027 (estimated)